ASB-16
目录号 : GB55066ASB-16是一种特异性的溶解剂,具有较强的膜亲和力,主要用于膜蛋白的提取和分析,常用于二维电泳和质谱分析中。
Cas No.:52562-29-5
Sample solution is provided at 25 µL, 10mM.
ASB-16 is a specific solubilizing agent with strong membrane affinity, primarily used for the extraction and analysis of membrane proteins, and is commonly employed in two-dimensional electrophoresis and mass spectrometry. Additionally, ASB-16 is a potent hemolytic agent with a high capacity for membrane disruption[1].
ASB-16 was used in a modified antigen removal (AR) tissue process to successfully create off-the-shelf small diameter (< 3mm) acellular vascular grafts from bovine saphenous vein ECM scaffolds, significantly reducing antigenic content while retaining the native vascular ECM protein structure and function[2]. The ASB-16-treated scaffold promoted the migration and proliferation of HUVECs (human umbilical vein endothelial cells). Furthermore, the ASB-16-treated acellular scaffold retained the original basement membrane and collagen structure[3-5].
ASB-16 improved the recellularization capacity and functionality of small-diameter vascular grafts in a rabbit model through an enhanced antigen removal treatment, including vascular patency and endothelial cell regeneration. Grafts treated with ASB-16 significantly reduced antigen content and increased compatibility with host tissue, thereby enhancing graft survival and overall function[2].
References:
[1]. Domingues CC, Malheiros SV, Paula Ed. Solubilization of human erythrocyte membranes by ASB detergents. Braz J Med Biol Res. 2008 Sep;41(9):758-64. doi: 10.1590/s0100-879x2008000900003. PMID: 18820764.
[2]. Lopera Higuita M, Lopera Giraldo JF, Sarrafian TL, Griffiths LG. Tissue engineered bovine saphenous vein extracellular matrix scaffolds produced via antigen removal achieve high in vivo patency rates. Acta Biomater. 2021 Oct 15;134:144-159. doi: 10.1016/j.actbio.2021.06.034. Epub 2021 Jun 27. PMID: 34192567; PMCID: PMC8542604.
[3]. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011 Apr;32(12):3233-43. doi: 10.1016/j.biomaterials.2011.01.057. Epub 2011 Feb 5. PMID: 21296410; PMCID: PMC3084613.
[4]. Wong ML, Wong JL, Vapniarsky N, Griffiths LG. In vivo xenogeneic scaffold fate is determined by residual antigenicity and extracellular matrix preservation. Biomaterials. 2016 Jun;92:1-12. doi: 10.1016/j.biomaterials.2016.03.024. Epub 2016 Mar 19. PMID: 27031928; PMCID: PMC5289067.
[5]. Hwang J, San BH, Turner NJ, White LJ, Faulk DM, Badylak SF, Li Y, Yu SM. Molecular assessment of collagen denaturation in decellularized tissues using a collagen hybridizing peptide. Acta Biomater. 2017 Apr 15;53:268-278. doi: 10.1016/j.actbio.2017.01.079. Epub 2017 Feb 1. PMID: 28161576; PMCID: PMC5462463.
ASB-16是一种特异性的溶解剂,具有较强的膜亲和力,主要用于膜蛋白的提取和分析,常用于二维电泳和质谱分析中。ASB-16也是一种强溶血剂,具有较高的膜破坏能力[1]。
使用含ASB-16的改良的抗原去除(AR)溶液处理组织,从牛隐静脉的细胞外基质支架中成功制备出小直径(<3mm)的无细胞血管移植物,显著降低了抗原含量,同时保留了原生血管细胞外基质的蛋白质结构和功能[2]。ASB-16处理的支架促进了HUVEC(人脐静脉内皮细胞)的迁移和增殖。ASB-16处理的无细胞支架保留了原有的基底膜和胶原蛋白结构[3-5]。
ASB-16在实验兔模型中通过改良的抗原去除处理,提高了小直径血管移植物的再细胞化能力和功能性,包括血管的通畅性和内皮细胞的再生能力。ASB-16处理的移植物能够显著降低抗原含量,提高与宿主组织的相容性,增强移植物的生存率和整体功能[2]。
Cell experiment [1]: | |
Cell lines | Erythrocytes |
Preparation Method | After centrifugation, the red blood cells were collected and washed with PBS buffer (5mM, pH 7.4) to adjust to the desired hematocrit levels (e.g., 0.15%, 0.30%, 0.45%, and 0.60%). Subsequently, ASB-16 was added to the red blood cell suspension for treatment at various concentrations, and the reaction was maintained at 37°C for 15 minutes. Following the reaction, the mixture was centrifuged at 15,000g for 30 minutes to separate the supernatant for analysis of soluble proteins and cholesterol. |
Reaction Conditions | 10-100μM ; 15-30mins |
Applications | ASB-16 was utilized for the analysis of membrane proteins and cholesterol solubilization, effectively enhancing the resolution of two-dimensional electrophoresis and facilitating the release of cholesterol from the red blood cell membrane. |
Animal experiment [2]: | |
Animal models | Rabbit |
Preparation Method | The acellular scaffold of ASB-16 was processed using antigen removal (AR) and SDS decellularization methods on saphenous veins (SV) to generate a decellularized scaffold. Prior to the surgical procedure, the rabbits were subjected to general anesthesia. The surgical site on the rabbits was disinfected, typically selecting suitable implantation locations such as the abdomen or hind limbs. |
Dosage form | 3% ASB-16; subcutaneous injection |
Applications | ASB-16 was applied to assess its potential in vascular regeneration and tissue engineering, including its effects on immune response, promotion of cell migration and proliferation, as well as the scaffold’s structural and functional integrity. |
References: |
Cas No. | 52562-29-5 | SDF | Download SDF |
分子式 | C24H50N2O4S | 分子量 | 462.73 |
溶解度 | 储存条件 | Store at 2-8°C | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.1611 mL | 10.8054 mL | 21.6109 mL |
5 mM | 0.4322 mL | 2.1611 mL | 4.3222 mL |
10 mM | 0.2161 mL | 1.0805 mL | 2.1611 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet